Clinical Trials Logo

Eosinophilic Gastritis clinical trials

View clinical trials related to Eosinophilic Gastritis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03678545 Active, not recruiting - Clinical trials for Eosinophilic Gastroenteritis

Dupilumab in Eosinophilic Gastritis

Start date: May 15, 2021
Phase: Phase 2
Study type: Interventional

40 participants with Eosinophilic Gastritis 12-70 years of age will be randomly assigned with dupilumab or placebo subcutaneous injections every two weeks for a total of 12 weeks. Study subjects who complete the 12-week treatment phase, may continue into an open label extension study, where dupilumab will be administered every two weeks for a total of 24 weeks.